Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,245 across all filing types
Latest filing 2023-01-24 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
We would like to inform you that, Board Meeting of the Company was held today i.e. Tuesday, January 24, 2023 at the registered office of the Company. In pursuant to Regulation 30 and 33 ....
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on January 24, 2023, where the Board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2022. It includes the unaudited financial results, notes, and the Limited Review Report by the auditors. The document references Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to quarterly financial results. The presence of unaudited financial statements and a limited review report indicates this is an Interim / Quarterly Report. The document length is about 15,000 characters, containing substantive financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2023-01-24 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on January 24, 2023, where the Board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2022. It includes the unaudited financial results and the Limited Review Report by the auditors. The document references Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to quarterly financial results. The presence of unaudited financial statements and a limited review report indicates this is an Interim / Quarterly Report. The document length is about 15,000 characters, containing substantive financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2023-01-24 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal notice addressed to stock exchanges about an upcoming Board Meeting scheduled for January 24, 2023. The purpose of the meeting is to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2022. The document also mentions the closure of the trading window for insiders until 48 hours after the announcement of these results. The document is short (1928 characters) and serves as an announcement of the meeting and the upcoming financial results, not the financial results report itself. Therefore, it is an announcement related to board/management activities but specifically about a meeting date and agenda, which fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a full Board/Management Information (MANG) which usually involves changes in board or management personnel.
2023-01-18 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal notice addressed to stock exchanges about an upcoming Board Meeting scheduled for January 24, 2023. The purpose of the meeting is to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2022. The document also mentions the closure of the trading window for insiders until 48 hours after the announcement of these financial results. The document is short (1904 characters) and serves as an announcement of a future event (Board Meeting) rather than containing any financial data or results itself. It does not contain actual financial statements or detailed analysis, nor is it a transcript or report. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2023-01-17 English
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2023 ,inter alia, to consider and approve the Unaudited Standalone ....
Board/Management Information Classification · 95% confidence The document is a formal notice addressed to stock exchanges about an upcoming Board Meeting scheduled for January 24, 2023. The purpose of the meeting is to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2022. The document also mentions the closure of the trading window for insiders in compliance with SEBI regulations. The document is short (1928 characters) and serves as an announcement of a future event (Board Meeting) rather than containing any financial results or detailed report itself. Therefore, it is not an Interim/Quarterly Report or Earnings Release but an announcement related to management activities. This fits the category of Board/Management Information (MANG).
2023-01-17 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2022. It is addressed to stock exchanges and confirms dematerialization/rematerialization of securities and related compliance. The document is short (3204 characters) and primarily serves as a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed financial data. It is not an announcement of a report but a regulatory filing confirming compliance with SEBI regulations. Therefore, it fits best under Regulatory Filings (RNS).
2023-01-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.